Truist has recently raised Sangamo Therapeutics Inc (SGMO) stock to Buy rating, as announced on December 13, 2024, according to Finviz. Earlier, on December 10, 2024, H.C. Wainwright had reiterated ...
We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Sangamo Therapeutics Inc (SGMO) stock saw a modest uptick, ending the day at $1.3 which represents a slight increase of $0.17 or 15.04% from the prior close of $1.13. The stock opened at $1.13 and ...
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...
SGMO’s stock crashed on the news. Sangamo is considering all options to continue the program, which includes looking for a new collaboration partner for the candidate. In July, the companies ...
SGMO’s stock crashed on the news. Sangamo is considering all options to continue the program, which includes looking for a new collaboration partner for the candidate. In July, the companies ...
SGMO stock opened at $1.03 on Thursday. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The stock has a 50-day moving average price of $2.14 and a 200-day moving average ...
Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investors concerning the Company’s possible ...
Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback